Keynote Lecture 4

Keynote Lecture 4

The last 6-12 months brought a significant change to the pharma industry. There is a growing consensus amongst the corporate executives that data need to be considered and, therefore, be treated as a – if not the most – precious asset of the industry. A couple of reasons hold accountable for this tremendous change of perception. New players have entered the scene not taking a lab-based but a data-based approach combining data access at scale with AI-based algorithms and high-performance computing. Personalized health-care and precision medicine require a data management strategy breaking up traditional silos within the organization ranging from real-world, diagnostic, clinical to pre-clinical and research data.

Assessing how the pharma industry has treated their corporate data assets so far leads to some interesting insights. The interoperability of data across repositories is rather poor, solutions to align data with standards are more tactical and only implemented when the pharma companies have a legal obligation to do so (such as CDISC or IDMP) and, finally as well as most surprisingly, data quality has not been too much in the focus so far. The huge gap between the clear need for high-quality and highly interoperable data on the one hand and the current status on the other end has led to a major challenge in the industry. Consequently, most companies have been elaborating remediation strategies where bio curation based on data standards and ontologies has become one of the main pillars.

In my presentation, I will provide a complete overview of the topic starting with some explanations why data assets have been strangely neglected in the Pharma Industry and move on to our current activities to data management using a layered approach where terminologies/ ontologies are constituting one of the reference SPoTs (single point of truth). I will then illustrate how we team up with (bio) curators in the organization and how we measure data quality. The presentation will close by highlighting the importance of precompetitive collaborations illustrating the value we could generate for the community.